Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy von Öberg, Kjell E, Reubi, Jean–Claude, Kwekkeboom, Dik J, Krenning, Eric P

Volltext

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus von Yao, James C, Pavel, Marianne, Phan, Alexandria T, Kulke, Matthew H, Hoosen, Sakina, St. Peter, Jessica, Cherfi, Azzeddine, Öberg, Kjell E

Volltext

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phas... von Kvols, Larry K, Oberg, Kjell E, O'Dorisio, Thomas M, Mohideen, Pharis, de Herder, Wouter W, Arnold, Rudolf, Hu, Ke, Zhang, Yilong, Hughes, Gareth, Anthony, Lowell, Wiedenmann, Bertram

Volltext

Malignant Gastric Ghrelinoma with Hyperghrelinemia von Tsolakis, Apostolos V., Portela-Gomes, Guida M., Stridsberg, Mats, Grimelius, Lars, Sundin, Anders, Eriksson, Barbro K., Öberg, Kjell E., Janson, Eva T.

Volltext

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors von Fjällskog, Marie‐Louise H., Granberg, Dan. P. K., Welin, Staffan L. V., Eriksson, Christopher, Kjell E. Öberg, Janson, Eva T., Eriksson, Barbro K.

Volltext

Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors von Fjällskog, Marie-Louise H., Janson, Eva T., Falkmer, Ursula G., Vatn, Morten H., Öberg, Kjell E., Eriksson, Barbro K.

Volltext

Expression of Molecular Targets for Tyrosine Kinase Receptor Antagonists in Malignant Endocrine Pancreatic Tumors von FJÄLLSKOG, Marie-Louise H, LEJONKLOU, Margareta H, ÖBERG, Kjell E, ERIKSSON, Barbro K, JANSON, Eva T

Volltext

Is it time to widen the use of somatostatin analogs in neuroendocrine tumors? von Oberg, Kjell E

Volltext

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours von WELIN, Staffan V, JANSON, Eva Tiensuu, SUNDIN, Anders, STRIDSBERG, Mats, LAVENIUS, Erik, GRANBERG, Dan, SKOGSEID, Britt, ÖBERG, Kjell E, ERIKSSON, Barbro K

Volltext

Gastrointestinal neuroendocrine tumors von Öberg, K E

Volltext

The Management of Neuroendocrine Tumours: Current and Future Medical Therapy Options von Oberg, K E

Volltext

Somatostatin induces rapid contraction of neuroendocrine cells von Saras, Jan, Grönberg, Malin, Stridsberg, Mats, Öberg, Kjell E., Janson, Eva T.

Volltext

NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dot... von Strosberg, Jonathan R., Wolin, Edward M., Chasen, Beth, Kulke, Matthew H., Bushnell, David L, Caplin, Martyn E., Baum, Richard P., Kunz, Pamela L., Hobday, Timothy J., Hendifar, Andrew Eugene, Oberg, Kjell E., Lopera Sierra, Maribel, Kwekkeboom, Dik J., Ruszniewski, Philippe B., Krenning, Eric

Volltext

Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET): A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with upd... von Strosberg, Jonathan R., Yao, James C., Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D., Ruszniewski, Philippe B., Van Cutsem, Eric, Oberg, Kjell E., Pavel, Marianne E.

Volltext

Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LU... von Ferolla, P., Brizzi, M. P., Meyer, T., Mansoor, W., Mazieres, J., Cao, C. D., Lena, H., Berruti, A., Damiano, V., Buikhuisen, W., Stankovic, M., Singh, N., Chiodini, E., Gislimberti, G., Öberg, Kjell E., Baudin, E.

Volltext

NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis von Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R., Kunz, P. L., Hobday, T., Hendifar, A., Öberg, Kjell E., Sierra, M. Lopera, Kwekkeboom, D., Ruszniewski, P., Krenning, E.

Volltext

Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome von Pavel, M. E., Gable, J., Kulke, M. H., Bergsland, E., Anthony, L. B., Caplin, M. E., Öberg, Kjell E., Banks, P., Yang, Q. M., Lapuerta, P., Hudgens, S.

Volltext

Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET): A Post-Hoc Analysis of the Placebo (PB... von Strosberg, Jonathan R., Yao, James C., Bajetta, Emilio, Aout, Mounir, Bakker, Bert, Hainsworth, John D., Ruszniewski, Philippe B., Van Cutsem, Eric, Öberg, Kjell E., Pavel, Marianne E.

Volltext

Everolimus plus octreotide long-acting release (LAR) for the treatment of advanced neuroendocrine tumors (NET) associated with carcinoid syndrome (RADIANT-2): Updated overall survi... von Pavel, M., Öberg, Kjell E., Hainsworth, J. D., Lam, D., Stergiopolos, S. G., Rouyrre, N., Peeters, M., Baudin, E., Gross, D., Yao, J. C.

Volltext

Everolimus Plus Octreotide Long-Acting Repeatable (LAR) for the Treatment of Advanced Neuroendocrine Tumors (NET) Associated with Carcinoid Syndrome: Updated Overall Survival Resul... von Yao, James C., Öberg, Kjell E., Hainsworth, John D., Lam, Du, Stergiopolos, Sotirios G., Rouyrre, Nicolas, Peeters, Marc, Baudin, Eric, Gross, David, Pavel, Marianne E.

Volltext